About BioCardia

We are a clinical-stage regenerative medicine company committed to improving the lives of patients suffering from cardiovascular diseases.

Our Mission: To bring to market comprehensive cell therapy solutions for the treatment of cardiovascular diseases with large unmet medical needs.

Our Pipeline: We are focused on developing therapeutic systems that include assays intended to screen and select subjects most likely to respond to therapy and delivery of a high target dose of cells utilizing a unique delivery system that has been shown to result in high cell retention.

Our lead therapeutic candidate is the investigational CardiAMP™ Cell Therapy System, which provides an autologous bone marrow derived cell therapy (using a patient's own cells) for the treatment of two clinical indications - heart failure that develops after a heart attack and chronic myocardial ischemia.

Our second therapeutic candidate is the investigational CardiALLO Cell Therapy System, an allogeneic "off the shelf" cell therapy derived from donor bone marrow cells that have been identified to meet specified criteria. This therapy has the potential to be advanced for many clinical indications including heart failure.



News


Have questions?
call us now
: (800) 624-1179
Have questions?
Email us now
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.